1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8:235–253. PMID:
19247306.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007; 282:26687–26695. PMID:
17623664.
3. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf). 2013; 78:489–496. PMID:
23134073.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Gimeno RE, Moller DE. FGF21-based pharmacotherapy: potential utility for metabolic disorders. Trends Endocrinol Metab. 2014; 25:303–311. PMID:
24709036.
5. Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One. 2012; 7:e33870. PMID:
22442730.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Ge H, Baribault H, Vonderfecht S, Lemon B, Weiszmann J, Gardner J, et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One. 2012; 7:e33603. PMID:
22457778.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010; 24:2050–2064. PMID:
20667984.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115:1627–1635. PMID:
15902306.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol. 2007; 210:1–6. PMID:
17063460.
10. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam M, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest. 2014; 124:515–527. PMID:
24401271.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Kim KH, Lee MS. FGF21 as a stress hormone: the roles of FGF21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J. 2014; 38:245–251. PMID:
25215270.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007; 5:426–437. PMID:
17550778.
13. Liang Q, Zhong L, Zhang J, Wang Y, Bornstein SR, Triggle CR, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014; 63:4064–4075. PMID:
25024372.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol. 2008; 74:403–412. PMID:
18467542.
15. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998; 47:507–514. PMID:
9568680.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell. 2012; 148:556–567. PMID:
22304921.
17. Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem. 2011; 286:34533–34541. PMID:
21846717.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013; 17:779–789. PMID:
23663741.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med. 2011; 17:736–740. PMID:
21373720.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012; 26:271–281. PMID:
22302939.
21. Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015; 58:464–473. PMID:
25425220.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010; 5:e15534. PMID:
21206918.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013; 33:2454–2459. PMID:
23887638.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Xiao Y, Liu L, Xu A, Zhou P, Long Z, Tu Y, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2015; 14:72. PMID:
26047614.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Zhang X, Hu Y, Zeng H, Li L, Zhao J, Zhao J, et al. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol. 2015; 14:32. PMID:
25850006.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011; 75:464–469. PMID:
21521346.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Lenart-Lipinska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract. 2013; 101:194–200. PMID:
23768789.
28. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57:1246–1253. PMID:
18252893.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008; 116:65–68. PMID:
17926232.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011; 34:2113–2115. PMID:
21750278.
31. Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens. 2013; 27:397–399. PMID:
23190795.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139:456–463. PMID:
20451522.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010; 40:887–892. PMID:
20624171.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Li X, Fan X, Ren F, Zhang Y, Shen C, Ren G, et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract. 2011; 93:10–16. PMID:
21596453.
![crossref](/image/icon/bnr_ref_cross.gif)
35. Lee CH, Hui EY, Woo YC, Yeung CY, Chow WS, Yuen MM, et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab. 2015; 100:1368–1375. PMID:
25625802.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009; 32:126–128. PMID:
18840768.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009; 94:2151–2156. PMID:
19318452.
38. Kaess BM, Barnes TA, Stark K, Charchar FJ, Waterworth D, Song K, et al. FGF21 signalling pathway and metabolic traits: genetic association analysis. Eur J Hum Genet. 2010; 18:1344–1348. PMID:
20717167.
39. Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015; 131:1861–1871. PMID:
25794851.
![crossref](/image/icon/bnr_ref_cross.gif)
40. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149:6018–6027. PMID:
18687777.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009; 58:250–259. PMID:
18840786.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007; 148:774–781. PMID:
17068132.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med. 2011; 3:113ra126.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes. 2012; 61:505–512. PMID:
22210323.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology. 2012; 153:4192–4203. PMID:
22798348.
46. Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med. 2012; 4:162ra153.
![crossref](/image/icon/bnr_ref_cross.gif)
47. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One. 2013; 8:e58575. PMID:
23536797.
![crossref](/image/icon/bnr_ref_cross.gif)
48. Adams AC, Halstead CA, Hansen BC, Irizarry AR, Martin JA, Myers SR, et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One. 2013; 8:e65763. PMID:
23823755.
![crossref](/image/icon/bnr_ref_cross.gif)
49. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther. 2013; 346:270–280. PMID:
23720456.
![crossref](/image/icon/bnr_ref_cross.gif)
50. Kim JH, Bae KH, Choi YK, Go Y, Choe M, Jeon YH, et al. Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabetes Obes Metab. 2015; 17:161–169. PMID:
25359298.
![crossref](/image/icon/bnr_ref_cross.gif)
51. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013; 18:333–340. PMID:
24011069.
![crossref](/image/icon/bnr_ref_cross.gif)
52. Dong JQ, Rossulek M, Somayaji VR, Baltrukonis D, Liang Y, Hudson K, et al. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br J Clin Pharmacol. 2015; 80:1051–1063. PMID:
25940675.
![crossref](/image/icon/bnr_ref_cross.gif)
53. Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016; 23:427–440. PMID:
26959184.
![crossref](/image/icon/bnr_ref_cross.gif)
54. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A. 2012; 109:3143–3148. PMID:
22315431.
55. Lee P, Linderman J, Smith S, Brychta RJ, Perron R, Idelson C, et al. Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos Int. 2013; 24:3053–3057. PMID:
23912560.
![crossref](/image/icon/bnr_ref_cross.gif)